Tiga Tablet 90 mg contains Ticagrelor 90 mg, an antiplatelet medication used to reduce the risk of heart attack, stroke, and other cardiovascular complications in patients with acute coronary syndromes (ACS) or a history of myocardial infarction. Ticagrelor is a potent P2Y12 receptor antagonist that prevents platelets from clumping together, reducing the formation of harmful blood clots in the arteries.

This therapy is often prescribed in combination with low-dose aspirin to provide dual antiplatelet therapy, which has been shown to significantly lower the risk of recurrent cardiovascular events in high-risk patients. Tiga Tablet 90 mg is particularly valuable for adults with unstable angina, non-ST elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI) after stabilization.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Ticagrelor 90 mg

Mechanism of Action

Ticagrelor works by selectively and reversibly binding to the P2Y12 receptor on platelets. By inhibiting this receptor, Ticagrelor prevents adenosine diphosphate (ADP)-mediated platelet activation and aggregation.

• Antiplatelet effect – Reduces platelet clumping, lowering the risk of thrombus formation in coronary arteries.

• Reversible action – Unlike some other antiplatelets, Ticagrelor’s effect is reversible, allowing more controlled platelet activity if necessary for surgery or in case of bleeding.

• Rapid onset – Provides faster platelet inhibition compared to some other P2Y12 inhibitors, offering timely protection in acute settings.

This dual mechanism ensures efficient prevention of clot formation while maintaining safety in long-term therapy.

Indications

Tiga Tablet 90 mg is indicated for:

• Prevention of atherothrombotic events in patients with acute coronary syndrome (ACS) including unstable angina, NSTEMI, or STEMI

• Reduction of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction

• Patients at high risk of thrombotic events following percutaneous coronary intervention (PCI)

It is prescribed as part of a comprehensive cardiovascular care plan under strict medical supervision.

Dosage and Administration

• The standard maintenance dose is 90 mg twice daily, taken orally.

• Usually administered in combination with low-dose aspirin (75–100 mg once daily).

• Swallow the tablet whole with water; do not crush or chew.

• Take at the same times every day to maintain consistent platelet inhibition.

• Adherence is crucial; missing doses increases the risk of cardiovascular events.

Benefits

• Provides effective prevention of recurrent heart attacks and strokes

• Rapid and potent platelet inhibition for acute and chronic cardiovascular risk management

• Reversible mechanism allows better control in case of bleeding or surgical procedures

• Can be combined safely with low-dose aspirin for dual antiplatelet therapy

• Improves long-term cardiovascular outcomes in high-risk patients

Precautions

• Increased risk of bleeding; avoid use in patients with active bleeding or hemorrhagic disorders.

• Use cautiously in patients with history of stroke, intracranial hemorrhage, or severe liver disease.

• Inform the physician about any upcoming surgeries, injuries, or use of other anticoagulants.

• Monitor for signs of abnormal bleeding, such as bruising, nosebleeds, or blood in stool/urine.

• Not recommended in pregnancy or breastfeeding unless specifically prescribed.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Shortness of breath (dyspnea)

• Headache

• Dizziness or lightheadedness

• Nausea

• Mild bleeding or bruising

Serious side effects requiring immediate medical attention:

• Severe or uncontrolled bleeding

• Allergic reactions (rash, swelling, difficulty breathing)

• Signs of stroke or heart attack

Storage

• Store below 30°C

• Keep in a cool, dry place

• Protect from moisture and direct sunlight

• Keep out of reach of children

Tiga Tablet 90 mg is a reliable antiplatelet medication for preventing cardiovascular events in high-risk patients, ensuring effective thrombus prevention when used under medical supervision.